Cspc Megalith Biopharmaceutical Co.,ltd.

This Phase 3 trial tests a new drug called SYS6010 against standard chemotherapy in 380 people with a specific type of advanced lung cancer (EGFR-mutated) that has stopped responding to targeted therapy. The goal is to see if SYS6010 can delay cancer growth better than chemo. Par…

This study tests two drugs together for people with advanced breast cancer that cannot be removed by surgery. SYS6023 targets a protein called HER3 on cancer cells, while KN026 targets HER2. The goal is to see if the combination is safe and shrinks tumors. About 36 adults with co…

This study tests a new drug called SYS6043 in people with advanced or metastatic solid tumors that have not responded to standard treatments. The drug is an antibody-drug conjugate designed to target and kill cancer cells. The trial will first find the safest dose, then expand to…

This Phase 2 trial is testing whether a combination of two drugs, SYS6010 and Enlonstobart, can shrink tumors or slow the growth of head and neck cancer that has come back or spread. About 70 adults aged 18-75 who have not had prior systemic treatment for their advanced cancer wi…